Table 1. Main definitions of Metabolic Syndrome.

WH0 (1998) [15]	NCEP/ATP III (2001-2005) [257]	IDF (2005) [258]
Insulin resistance or diabetes or impaired glucose tolerance or impaired fasting glucose, plus two of these conditions	At least 3 of the following:	Abdominal obesity defined as waist circumference ≥ 94 cm in men and ≥80 cm in womenPlus at least two of the following criteria:
✓ Body mass index ≥30kg/m2 or waist ratio >0,9 man/ 0,85woman;	✓ Waist circumferences ≥ 102cm man and 88 woman;	✓ Increased fasting tryglicerides > 150 mg/dl (≥1,7 mmol/l) or lipid lowering treatment;
✓ Blood pressure≥ 140/90 mmHg or antihypertensive treatment;	✓ Blood pressure ≥ 130/85 mmHg, or antihypertensive treatment;	✓ HDL < 0,9 mmol/l (40 mg/dl) man <1,1 (50 mg/dl) women or lipid lowering treatment;
✓ Triglycerides≥ 1,7 mmol/(150 mg/dl) or lipid lowering treatment;	✓ Triglycerides ≥ 1,7 mmol/(150 mg/dl) or lipid lowering treatment;	✓ Increased blood pressure ≥ 130/85 mmHg, or antihypertensive treatment;
✓ HDL < 0,9 mmol/l (35 mg/dl) man <1,0 (39 mg/dl) woman;	✓ HDL < 1 mmol/l (39 mg/dl) man <1,3 (50 mg/dl) woman;	✓ High level of fasting glucose > 100 mg/dl (5,6 mmol/l), or T2DM;
✓ Glucose 5,6 mmol/dl (101 mg/dl) or hypoglycemic treatment;	✓ Glucose 5,6 mmol/dl (101 mg/dl) or hypoglycemic treatment;
✓ Microalbuminuria;
Legend Table 1:  HDL: High Density Lipoprotein  IDF: International Diabetes Federation  NCEP ATP III: National Cholesterol Education Program's Adult Treatment Panel III report  T2DM: type 2 diabetes mellitus  WHO: World Healt Organization

Main definitions drawn up by the WHO, NCEP/ ATP III and IDF of MetS recognized by the scientific world.